C-myc and c-fos in human osteosarcoma: Prognostic value of mRNA and protein expression

Oncology

Volumn 55, Issue 6, 1998, Pages 556-563

  Gamberi, Gabriella ^a   Benassi, M Serena ^a   Bohling, Tom ^b   Ragazzini, Paola ^a   Molendini, Lara ^a   Sollazzo, M Rosa ^a   Pompetti, Franca ^c   Merli, Mara ^a   Magagnoli, Giovanna ^a   Balladelli, Alba ^a   Picci, Piero ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF CHIETI   (Italy)

Author keywords

Oncogene; Osteosarcoma; Prognosis

Indexed keywords

MESSENGER RNA; MYC PROTEIN; PROTEIN C FOS;

ADOLESCENT; ADULT; AGED; ARTICLE; CARCINOGENESIS; CELL GROWTH; CHILD; CLINICAL ARTICLE; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; MALE; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTO ONCOGENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; AGED; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION; GENES, FOS; GENES, MYC; HUMANS; MALE; MIDDLE AGED; OSTEOSARCOMA; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-MYC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 0031783711     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000011912     Document Type: Article

References (40)

1. Carbone M, Levine AS: Oncogenes, antioncogenes and the regulation of cell growth. TEM 1990;1:248-253.
2. Cooper GM: Oncogenes. Boston, Jones & Bartlett Publishers, 1995.
3. Perucho M, Goldfarb M, Shimizu K, Lama C, Fogh J, Wigler M: Human tumor derived cell lines contain common and different transforming genes. Cell 1981;27:467-476.
4. Murray MJ, Shilo BZ, Shin C, Cowing D, Hsu HW, Weinberg RA: Three different tumor cell lines contain different oncogenes. Cell 1981;25: 355-361.
5. Pulciani S, Santos E, Lauver AV, Long LK, Aaronson SA, Barbacid M: Oncogenes in human bone tumors. Nature 1982;300:539-542.
6. Brodreur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM: Amplification of N-myc in untreated human neuroblastoma correlated with advanced disease stage. Science 1984;224: 1121-1124.
7. Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Sigurdsson H: Erbb2 amplification in breast cancer with a high rate of proliferation. Oncogene 1991;6:137-143.
8. Berns EMJJ, Klijn JGM, van Putten WLJ, van Staversen IL, Portengen H, Foekes JA: C-myc amplification is a better prognostic factor than HER2:neu amplification in primary breast cancer. Cancer Res 1992;52:1107-1113.
9. Blackwood EM, Eiseman JK: Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA binding complex with myc. Science 1991;250:1149-1151.
10. Collins S, Groudine M: Amplification of endogenous myc-related DNA sequences in a human myeloid leukaemia cell line. Nature 1982; 298:679-681.
11. Dalla-Favera R, Wong-Staal F, Gallo RC: Oncogene amplification in promyelocytic leukaemia cell line HL-60 and primary leukaemic cells of the same patients. Nature 1982;229:61-63.
12. Sheiness D, Bishop JM: DNA and RNA from uninfected vertebrate cells contain nucleotide sequences related to the putative transforming gene of avian myelocytomatosis virus. J Virol 1987;31:465-475.
13. Barrios H, Castresana JS, Ruiz J, Kreicbergs A: Amplification of the c-myc proto-oncogene in soft tissue sarcomas. Oncology 1994;51:13-17.
14. Rauscher FJ, Sanbucetti LC, Curran T, Distel RJ, Spiegelman BM: Common DNA binding site for fos protein complexes and transcription factor AP1. Cell 1988;52:471-480.
15. Sassone-Corsi P, Lamph WW, Kamps M, Verma IM: Fos associated cellular p39 is related to nuclear transcription factor AP1. Cell 1988;54: 553-560.
16. Kouzarides T, Ziff E: The role of the leucine zipper in the fos-jun interaction. Nature 1988; 336:646-651.
17. Van den Berg S, Rahmsdorf HJ, Herrlich P, Kaina B: Overexpression of the c-fos increases recombination frequency in human osteosarcoma cells. Carcinogenesis 1993;14:925-928.
18. Wang Z, Grigoriadis AE, Wagner EF: Stable murine chondrogenic cell lines derived from c-fos induced cartilage tumors. J Bone Miner Res 1993;8:839-847.
19. Miller AD, Curran C, Verma ID: C-fos protein can induce cellular transformation: A novel mechanism of activation of a cellular oncogene. Cell 1984;36:51-60.
20. Ward JM, Young D: Histogenesis and morphology of periosteal sarcomas induced by FBJ virus in NIH Swiss mice. Cancer Res 1976;36: 3985-3992.
21. Grigoriadis AE, Wang Z, Wagner EF: Fos and bone cell development: Lessons from a nuclear oncogene. Trends Genet 1995;11:436-441.
22. Campanacci M: Bone and Soft Tissue Tumors. New York, Springer, 1990.
23. Bieling P, Rehan N, Winkler P, Helmke K, Maas R, Fuchs N, Bielack S, Heise U, Jurgens H, Treuner J, Romanowski R, Exner U, Kotz R, Winkler K: Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol 1996;14:848-858.
24. Sambrook J, Fritsch RF, Maniatis R: Molecular Cloning, a Laboratory Manual. Cold Spring Harbor, Cold Spring Laboratory, 1989.
25. Chelly J, Kahn A: RT-PCR and mRNA quantitation; in Mullis K, Gibbs R (eds): The Polymerase Chain Reaction. Boston, Birkhäuser, 1994, pp 98-109.
26. Chomczynski P, Sacchi N: Single-step methods of RNA isolation by acid guanidium thiocyanate phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
27. Grande A, Manfredini R, Tagliafico E, Balestri R, Pizzanelli M, Papa S, Zucchini P, Bonsi L, Bagnara G, Torelli U, Ferrari S: All trans-retinoic acid induces simultaneously granulocytic differentiation and expression of inflammatory cytokines in HL-60 cells. Exp Hematol 1995; 23:117-125.
28. Murphy LD, Herzog CE, Rudick JB, Fojo AT, Bates SE: Use of the polymerase chain reaction in the quantitation of mdr-1 gene expression. Biochemistry 1990;29:10351-10356.
29. Noonan KE, Beck C, Holzmayer TA, Chin JE, Wunder JS, Andrulis IL, Gazdar AF, Willman CL, Griffith B, von Hoff DD, Roninson IB: Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 1990;87:7160-7164.
30. von Boguslawsky K: Immunohistochemical detection of progesterone receptors in paraffin sections. APMIS 1994;102:641-646.
31. Dijkman HBPM, Mentzel S, De Jong AS, Assmann KJM: RNA in situ hybridization using DIG-labeled cRNA probes; in Grunewald-Janho S, Keesey J (eds): Nonradioactive in situ Hybridization Application Manual. Mannheim, Boehringer Mannheim, 1996, pp 152-157.
32. Gulisano M, Boncinelli E: Biologia Molecolare: Ibridazione in situ. Genova, Recco, 1995.
33. Barrios C, Castresana JS, Kreicbergs A: Clinicopathologic correlations and short-term prognosis in musculoskeletal sarcoma with c-myc oncogene amplification. Am J Clin Oncol 1994;17:273-276.
34. Barrios C, Castresana JS, Ruiz J, Kreicbergs A: Amplification of c-myc oncogene and absence of c-Ha-ras point mutations in human bone sarcomas. J Orthop Res 1993;11:556-563.
35. Shin K-H, Rougraff BT, Simon MA: Oncologic outcomes of primary bone sarcomas of the pelvis. Clin Orthop 1994;304:207-217.
36. Tatosyan AG, Galetzki SA, Kisseljova NP: Oncogene expression in human tumors. Int J Cancer 1985;35:731-736.
37. Okazaki R, Ikeda K, Sakamoto A, Nakano T, Morimoto K, Kikuchi T, Urakawa K, Ogata E, Matsumoto T: Transcriptional activation of c-fos and c-jun protooncogenes by serum growth factors in osteoblast-like MC3T3-E1 cells. J Bone Miner Res 1992;7:1149-1155.
38. Hoyland J, Sharpe JH: Upregulation of c-fos proto-oncogene expression in pagetic osteoclasts. J Bone Miner Res 1994;9:1191-1194.
39. Grigoriadis AE, Schellander K, Wang Z, Wagner EF: Osteoblasts are target cells for transformation in c-fos transgenic mice. J Cell Biol 1993;122:685-701.
40. Land H, Parada LF, Weinberg RA: Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 1983;304:596-602.